Innoviva Cash on Hand 2010-2023 | INVA

Innoviva cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Innoviva Annual Cash on Hand
(Millions of US $)
2023 $194
2022 $291
2021 $202
2020 $246
2019 $351
2018 $115
2017 $129
2016 $150
2015 $187
2014 $240
2013 $465
2012 $248
2011 $241
2010 $310
2009 $155
Innoviva Quarterly Cash on Hand
(Millions of US $)
2023-12-31 $194
2023-09-30 $180
2023-06-30 $173
2023-03-31 $144
2022-12-31 $291
2022-09-30 $301
2022-06-30 $284
2022-03-31 $217
2021-12-31 $202
2021-09-30 $135
2021-06-30 $43
2021-03-31 $283
2020-12-31 $246
2020-09-30 $479
2020-06-30 $417
2020-03-31 $384
2019-12-31 $351
2019-09-30 $297
2019-06-30 $250
2019-03-31 $192
2018-12-31 $115
2018-09-30 $55
2018-06-30 $108
2018-03-31 $56
2017-12-31 $129
2017-09-30 $168
2017-06-30 $136
2017-03-31 $170
2016-12-31 $150
2016-09-30 $149
2016-06-30 $154
2016-03-31 $168
2015-12-31 $187
2015-09-30 $206
2015-06-30 $229
2015-03-31 $251
2014-12-31 $240
2014-09-30 $269
2014-06-30 $349
2014-03-31 $371
2013-12-31 $465
2013-09-30 $506
2013-06-30 $443
2013-03-31 $459
2012-12-31 $248
2012-09-30 $273
2012-06-30 $295
2012-03-31 $200
2011-12-31 $241
2011-09-30 $265
2011-06-30 $284
2011-03-31 $294
2010-12-31 $310
2010-09-30 $192
2010-06-30 $211
2010-03-31 $225
2009-12-31 $155
2009-09-30 $154
2009-06-30 $176
2009-03-31 $179
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.959B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $708.528B 117.99
Novo Nordisk (NVO) Denmark $577.276B 47.56
Johnson & Johnson (JNJ) United States $360.407B 14.30
Merck (MRK) United States $321.391B 84.59
AbbVie (ABBV) United States $300.196B 15.26
AstraZeneca (AZN) United Kingdom $219.666B 19.46
Novartis AG (NVS) Switzerland $198.840B 14.10
Pfizer (PFE) United States $149.038B 14.38
Sanofi (SNY) $120.637B 10.86